| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 13.88 | 11.1% | 22.1% |
| Total Income | 13.88 | 11.1% | 22.1% |
| Expenditure | 15.69 | 17.1% | 12.5% |
| PBT | -2.95 | 47.5% | 20.1% |
| Net Profit | -3.24 | 53.5% | 14.3% |
| OPM | -13.01% | 5.71pp | 9.63pp |
| NPM | -23.36% | 6.48pp | 9.86pp |
| EPS | -0.07 | 40.0% | 22.2% |
Apyx Medical Reports Q2 2026 Financial Results
07 Aug 2026 · 7 Aug, 1:51 am
Summary
Apyx Medical Corporation reported a 22.1% increase in total revenue for the second quarter of 2026, reaching $13.9 million, primarily driven by a 28.1% surge in its Surgical Aesthetics segment. The company also reported an improved net loss of $3.2 million and a reduced Adjusted EBITDA loss of $0.7 million compared to the prior year. Management reaffirmed its full-year revenue guidance of $59.0 million to $60.0 million, expressing confidence in the continued growth driven by the AYON platform and expanding clinical evidence.
Key Highlights
- 1
Apyx Medical reported total revenue of $13.9 million in the second quarter of 2026, an increase of 22.1% compared to $11.4 million in the prior year period.
- 2
Surgical Aesthetics revenue increased by 28.1% to $12.4 million in the second quarter of 2026, driven by sales of AYON and Renuvion generators.
- 3
OEM segment revenue decreased by 12.0% to approximately $1.5 million in the second quarter of 2026.
- 4
Net loss attributable to stockholders was $3.2 million, or $0.07 per share, for the second quarter of 2026, an improvement from a net loss of $3.8 million, or $0.09 per share, in the prior year period.
- 5
Adjusted EBITDA loss for the second quarter of 2026 was $0.7 million, an improvement from an Adjusted EBITDA loss of $2.0 million in the second quarter of 2025.
- 6
The company reaffirmed its financial guidance for FY2026, expecting total revenue in the range of $59.0 million to $60.0 million.
Management Comments
Charlie Goodwin
We are excited by the increasing demand for AYON throughout the U.S. market, which we believe reflects the successful execution of our commercial strategy. As a result, we reported 28% growth for the Surgical Aesthetics segment and expect AYON to continue to drive growth through the second half of the year. U.S. Surgeons continue to recognize the value of an all-in-one body contouring platform that brings together the technologies they rely on every day. With the recent FDA clearance of AYON's power liposuction capability, we are executing a measured rollout with key surgeons ahead of a initial commercial shipments in June. Alongside the expanding body of clinical evidence supporting Renuvion, these milestones reinforce our confidence in the long-term growth opportunity for our business.
Informational and educational content only. Not investment advice.